CIAM
JBIO

Caitong International Asset Management’s Jade Biosciences JBIO Stock Holding History

Caitong International Asset Management’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$89 Buy
4
+3
+300% +$63 ﹤0.01% 2212
2026
Q1 		$14 Buy
+1
New +$14 ﹤0.01% 2106

Other funds holding JBIO

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
State of New Jersey Common Pension Fund D
State of New Jersey Common Pension Fund D Trenton, New Jersey $29.3B AUM 38.15% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Caitong International Asset Management's JBIO Position: Q2 2026 in Review

Caitong International Asset Management increased its Jade Biosciences (JBIO) stake by 300% in Q2 2026, buying an estimated $63 and bringing the position to 4 shares worth $89. The position accounts for ﹤0.01% of the portfolio, ranked #2212.

Caitong International Asset Management first reported a position in JBIO in Q1 2026 and has held it in 2 quarters since. 34 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • Caitong International Asset Management held 4 shares of Jade Biosciences worth $89 as of Q2 2026.
  • Caitong International Asset Management bought 3 Jade Biosciences shares in Q2 2026, an estimated $63.
  • Jade Biosciences made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #2212 holding.
  • Caitong International Asset Management first reported a position in Jade Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 34 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.